Unknown.png
Beta Bionics Appoints Martha Aronson and Sean Carney to Its Board as Independent Directors
February 20, 2020 08:00 ET | Beta Bionics
WEST CONCORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas...
Unknown.png
Beta Bionics Receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System
December 10, 2019 02:00 ET | Beta Bionics
The iLet is a pocket-sized, wearable investigational medical device that autonomously controls blood sugar in people with diabetes and other conditions -- it is the world’s first bionic pancreas...
BetaBionics.png
Encouraging Results of Pilot Study Testing Bionic Pancreas in Cystic Fibrosis-Related Diabetes Published in Journal of Cystic Fibrosis
December 03, 2019 08:00 ET | Beta Bionics
A pilot study performed by researchers at the Massachusetts General Hospital tested autonomous glycemic control using the bionic pancreas system in both insulin-only and bihormonal...
BetaBionics.png
Beta Bionics and ConvaTec Announce Partnership to Bring Unomedical Infusion Set Portfolio to the iLet™ Bionic Pancreas System
July 17, 2019 08:00 ET | Beta Bionics
ConvaTec is a leading global manufacturer of widely popular infusion sets offering a variety of patient choice Beta Bionics is developer of the iLet Bionic Pancreas System and is committed to device...
BetaBionics.png
Beta Bionics Announces Closing of a $63 Million Series B2 Financing, Bringing the Total Series B and B2 Financings to $126 Million
July 01, 2019 14:50 ET | Beta Bionics
The round was co-led by new investors Perceptive Advisors and Soleus CapitalNew investor Farallon Capital also participated in the round, as did previous Series B investors RTW Investments, ArrowMark...
BetaBionics.png
Beta Bionics Announces Final Closing of Its $63 Million Series B Financing
January 08, 2019 16:19 ET | Beta Bionics
New investors include ArrowMark, LifeSci Venture Partners, and strategic partner, DexcomRTW made an additional Series B investmentStrategic partner, Zealand Pharma completed $5 million Series B...
BetaBionics.png
Beta Bionics Awarded Up to $2 Million NIH Small Business Innovation Research (SBIR) Grant
October 09, 2018 12:46 ET | Beta Bionics
Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Grant provides up to $2 million in funding over the next 24 months under the Fast-Track mechanism (pending...
BetaBionics.png
Beta Bionics Secures an Initial $50 Million Series B Round
September 17, 2018 09:16 ET | Beta Bionics
The round was led by Eventide Asset ManagementOther institutional investors in Series B include RTW InvestmentsCorporate strategic partner and Series A investor, Novo Nordisk, has also participated in...
BetaBionics.png
Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet
July 12, 2018 08:00 ET | Beta Bionics
The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in adults with type 1 diabetes (T1D) using two highly accurate continuous glucose monitoring (CGM) systems: the Dexcom...
Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System
May 21, 2018 08:00 ET | Beta Bionics
First trial to test Fiasp® – Novo Nordisk’s latest formulation of fast-acting insulin aspart – using autonomous insulin delivery The bionic pancreas will also be tested with the conventional...